First Capital Ventures

B-Secur Ltd., founded in 1996 and based in Belfast, United Kingdom, specializes in ECG biometric software that enhances digital security by using an individual's unique heartbeat pattern for identity verification. The company has invested over 15 years in scientific research to develop advanced ECG technology, positioning itself as a leader in the field. B-Secur's flagship product, HeartKey®, offers physiological monitoring with robust data protection, making it suitable for integration into various devices and systems. The company has developed a comprehensive suite of ECG algorithms and analytics focused on user identification, wellness, and health, enabling businesses to streamline authentication processes. With over 50 years of combined expertise in hardware and material science, B-Secur provides partners with resources to reduce development costs related to hardware and ECG electrode design, thus enhancing their competitive edge in the market.

KromaTiD, Inc. is an early-stage bioscience company based in Fort Collins, Colorado, established in 2007. The company specializes in chromosome analysis products aimed at advancing the understanding of genetic abnormalities and diseases. KromaTiD develops molecular cytogenetic assays and reagents, including its proprietary Directional Genomic Hybridization (dGH) technology, which enhances standard fluorescence in situ hybridization (FISH) assays. These tools enable researchers to discover, detect, and diagnose various disease-causing mutations, such as inversions and translocations, from single cells. KromaTiD’s offerings include assays for targeting entire chromosomes or individual chromatids, inversion detection solutions, and custom assays covering the entire human genome. Their products are designed to support biomedical research and medical testing applications, facilitating advancements in oncology and rare diseases, and assisting research teams in academia and the biopharma sector in developing novel therapeutics.